Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.53
+0.11000.71%
Post-market: 15.530.00000.00%19:30 EDT
Volume:3.29M
Turnover:51.08M
Market Cap:3.13B
PE:-18.79
High:15.62
Open:15.62
Low:15.39
Close:15.42
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.94
T/O Rate:1.68%
Dividend:1
Dividend Rate:6.44%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.01
PE(LYR):-10.86

Loading ...

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

GlobeNewswire
·
Yesterday

Park Hotels & Resorts (PK) Could Be 25% Undervalued On Its Debt Refinance

Simply Wall St.
·
Oct 01

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

GlobeNewswire
·
Oct 01

Park Hotels & Resorts Repays USD 1.28 Billion Hilton Hawaiian Village Mortgage Loan

Reuters
·
Oct 01

Park Hotels & Resorts - Extends Weighted-Average Debt Maturity to 3.1 Years; Less than 11% Debt Matures Through 2027

THOMSON REUTERS
·
Oct 01

Park Hotels & Resorts - Repayment Funded by $700 Mln Bonnet Creek Mortgage and $600 Mln Term Loan Facility

THOMSON REUTERS
·
Oct 01

Press Release: Avacta Group Plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Dow Jones
·
Sep 30

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

GlobeNewswire
·
Sep 29

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

GlobeNewswire
·
Sep 29

M Core Acquires Newcastle Leisure Complex the Gate

Reuters
·
Sep 28

Park Hotels & Resorts Inc : Raymond James Raises to Strong Buy from Market Perform

THOMSON REUTERS
·
Sep 28

Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

GlobeNewswire
·
Sep 25

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

GlobeNewswire
·
Sep 16

Truist Financial Sticks to Its Hold Rating for Park Hotels & Resorts (PK)

TIPRANKS
·
Sep 15

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

GlobeNewswire
·
Sep 15

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

GlobeNewswire
·
Sep 15

Park Hotels & Resorts Schedules Third-Quarter Earnings Call

Reuters
·
Sep 11

Park Hotels’ CIO Thomas Morey Departs

Reuters
·
Sep 11

Park Hotels Grants CEO Baltimore 331,564-Share Retention Award

Reuters
·
Sep 11

Truist Securities Adjusts Price Target on Park Hotels & Resorts to $17 From $13, Keeps Hold Rating

MT Newswires Live
·
Sep 10